Persistent Coagulopathy After Synthetic Cannabinoid Use

Division

West Florida

Hospital

Brandon Regional Hospital

Document Type

Case Report

Publication Date

3-1-2023

Keywords

brodafacoum, long-acting anticoagulant, superwarfarin, synthetic cannabinoids, vitamin k1

Disciplines

Internal Medicine | Pathological Conditions, Signs and Symptoms

Abstract

Synthetic cannabinoids (SCs) are chemical compounds created and manufactured, without quality control standards or requirements, to mimic tetrahydrocannabinol (THC). They are widely available in the USA, and they are sold under various brand names, including "K2" and "spice." Many adverse effects have been attributed to SCs, but most recently, they have also been associated with bleeding. There have been reported cases around the globe of SCs contaminated with long-acting anticoagulant rodenticide (LAAR) or superwarfarins. They are developed from compounds such as bromethalin, brodifacoum (BDF), and dicoumarol. LAAR exhibits their mechanism as a vitamin K antagonist inhibiting vitamin K 2,3-epoxide reductase, preventing activation of vitamin K1 (phytonadione). Therefore, reducing the activation of clotting factors II, VII, IX, and X and proteins C and S. In contrast to warfarin, BDF has an extremely long-acting biological half-life of 90 days due to minimal metabolism and limited clearance. Here, we report a 45-year-old male who presented to the emergency room with a 12-day history of gross hematuria and mucosal bleeding without previous history of coagulopathy and recurrent SCs use.

Publisher or Conference

Cureus

Link to Full Text

Share

COinS